Quest Diagnostics Incorporated is a clinical diagnostics company that provides laboratory testing services and diagnostic insights to healthcare providers, patients, and organizations. The company operates through three primary customer channels: physicians, hospitals, and patients and consumers. For physicians, it offers a comprehensive test menu and data-powered integrated information-technology solutions. For hospitals, it provides reference testing, Collaborative Lab Solutions for lab management outsourcing and supply chain management, and joint venture arrangements for diagnostic information services. For patients and consumers, it operates patient service centers, offers mobile phlebotomy services, and provides consumer-initiated testing through the QuestHealth.com platform. The company also serves employers with workforce drug screening and population health solutions, and supports pharmaceutical companies with clinical trial services. Quest Diagnostics serves approximately one-third of the adult population of the United States annually and approximately half of the physicians and hospitals in the United States. The company was incorporated in 1990, with predecessor companies dating back to 1967.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Diagnostics & Research Homepage questdiagnostics.com
Sector Healthcare IR page ir.questdiagnostics.com/overview/default.aspx
Tags
clinical diagnostics, laboratory testing, reference testing, collaborative lab solutions, consumer health, workplace drug screening, clinical trials, biomarker testing, population health, infectious diseases, cardiometabolic health, liver disease diagnostics, QuestHealth.com, MyQuest, Quanum Lab Services Manager, Clinical Insights Companion, Quest Lab Alert, Professional Laboratory Services, QUEST AD-Detect Amyloid Beta 42/40, ELF Score, Clinical Education Center, Test Directory
Press page —

Metrics

Valuation  
Market cap $ 28.624B
Market cap (USD) $ 28.624B
P/E 25.91
PEG 16.24
P/BV 3.75
P/S 2.42
P/OCF 14.67
P/FCF 20.82
Dividend yield 1.3%
Turnover / mcap —
Returns  
ROE 14.2%
ROI 7.7%
ROIC 9.2%
Profit margin 9.0%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 1.6%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 72.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 44
Quality score 15.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 11.035B 9.872B 9.252B 9.883B 10.788B 9.437B 7.726B 7.531B 7.709B 7.515B 7.493B 7.435B 7.146B 7.383B 7.51B 7.369B 7.455B 7.249B 6.705B 6.269B 5.504B 5.127B 4.738B 4.108B 3.628B 3.421B
Net profit 992M 871M 854M 946M 1.995B 1.431B 858M 736M 772M 645M 709M 556M 849M 555.721M 470.567M 720.894M 729.111M 581.49M 339.939M 586.421M 546.277M 499.195M 436.717M 322.154M 162.303M 102.052M
Free cash flow 1.359B 909M 864M 1.314B 1.83B 1.587B 843M 817M 923M 776M 547M 630M 421M 1.005B 733.918M 912.647M 830.49M 850.368M 707.823M 758.474M 627.313M 622.655M 488.158M 441.175M 316.817M 253.005M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 173.53 150.86 137.88 156.44 173.01 119.17 106.79 83.27 98.49 91.9 71.14 67.06 53.54 58.27 58.05 53.97 60.38 51.86 55.51 49.59 — — — — — —
Price performance 12m 0.15 0.09 -0.12 -0.1 0.45 0.12 0.28 -0.15 0.07 0.29 0.06 0.25 -0.08 0 0.08 -0.11 0.16 -0.07 0.12 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 926M 924M 1.01B 1.06B 1.52B 1.44B 1.2B 1.21B 1.3B 1.41B
↳ YoY growth +2.8% -0.2% +9.5% +5.0% +43.0% -5.4% -16.9% +1.3% +7.8% +8.0%
↳ 5y CAGR +0.4% +1.3% +3.5% +2.7% +11.0% +9.2% +5.3% +3.6% +4.2% -1.5%
Borrowings, current (USD) 6M 36M 464M 804M 2M 2M 2M 303M 602M 504M
Borrowings, non-current (USD) 3.73B 3.75B 3.43B 3.97B 4.01B 4.01B 3.98B 4.41B 5.62B 5.17B
Lease liabilities (USD) — — 0.00 591M 667M 679M 651M 663M 725M 732M
Cash and deposits (USD) 359M 137M 135M 1.19B 1.16B 872M 315M 686M 549M 420M
Intangible assets (USD) 949M 1.12B 1.21B 1.12B 1.17B 1.17B 1.09B 1.17B 1.76B 1.64B
Right-of-use assets (USD) — — 0.00 518M 604M 597M 585M 602M 651M 657M
Net debt (borrowings + leases - cash) (USD) 3.38B 3.65B 3.76B 4.17B 3.52B 3.82B 4.32B 4.69B 6.39B 5.98B
Cash flow detail
Operating cash flow (USD) 1.07B 1.18B 1.2B 1.24B 2.01B 2.23B 1.72B 1.27B 1.33B 1.89B
Purchases of property, plant and equipment (USD) -293M -252M -383M -400M -418M -403M -404M -408M -425M -527M
Change in receivables (cash effect) (USD) -343M -298M -65M -63M -455M 81M 246M -15M -71M -106M
Change in payables (cash effect) (USD) 56M -8M -19M 73M 452M 35M -149M -55M -67M 129M
Dividends paid (cash effect) (USD) -223M -247M -266M -286M -297M -309M -305M -314M -331M -353M
Share buybacks (cash effect) (USD) -590M -465M -322M -353M -325M -2.2B -1.41B -275M -151M -450M
Interest paid (cash effect) (USD) -148M -159M -174M -192M -201M -159M -156M -134M -262M -280M
Income taxes paid (cash effect) (USD) -361M -243M -84M -202M -360M -709M -283M -317M -256M -169M
Share-based compensation (USD) 69M 79M 61M 56M 97M 79M 77M 77M 88M 88M
Operating cash flow before change in receivables (USD) 1.41B 1.47B 1.27B 1.31B 2.46B 2.15B 1.47B 1.29B 1.41B 1.99B
Free cash flow (OCF - PPE - intangibles) (USD) 776M 923M 817M 843M 1.59B 1.83B 1.31B 864M 909M 1.36B
Income detail
Total comprehensive income (USD) 662M 848M 779M 926M 1.52B 2.09B 1.01B 915M 847M 1.11B
Comprehensive income to owners (USD) 611M 796M 727M 878M 1.45B 2B 939M 861M 797M 1.05B
Provision for credit losses (USD) 308M 315M 6M 11M 19M 4M 3M 1M 5M —
Credit cost ratio (credit losses / average receivables) (%) 33.7% 34.1% 0.6% 1.1% 1.5% 0.3% 0.2% 0.1% 0.4% —
Reported Feb 22, 2017 Feb 23, 2018 Apr 24, 2019 Feb 20, 2020 Feb 22, 2021 Feb 28, 2022 Feb 21, 2023 Feb 22, 2024 Feb 20, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

10/22/2026

  • Download (opens in new window)

  • Third quarter revenues of $3.10 billion, up 10.0% from 2025, on strong organic revenue growth

  • Third quarter reported diluted earnings per share ("EPS") of $2.78, up 28.7% from 2025; and adjusted diluted EPS of $3.00, up 15.4% from 2025

  • Full year 2026 revenues now expected to be between $12.065 billion and $12.105 billion

  • Full year 2026 reported diluted EPS now expected to be between $10.21 and $10.31; and adjusted diluted EPS expected to be between $11.25 and $11.35

SECAUCUS, N.J., Oct. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2026.

"We delivered revenue growth of 10% and adjusted EPS growth of over 15% on continued strength across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI," said Jim Davis, Chairman, CEO and President. "Our robust organic revenue growth demonstrates that our solutions are fulfilling the expanding clinical care needs of an aging population as well as the increasing number of people focused on prevention and wellness. With these growth trends and our strong performance, we are raising our revenue and EPS guidance for the full year."

Recent Highlights:

  • Announced the ability for iPhone and iPad users in the United States to conveniently purchase a tailored Quest laboratory test panel with over 50 biomarkers directly through the Apple Health app, available to the public later this year.

  • Finalized a definitive agreement to acquire select outreach lab assets from a leading health system and long-time Co-Lab Solutions customer in the Northeastern U.S. Continued to advance our Co-Lab Solutions implementation and joint venture lab with Corewell Health in Michigan.

  • Extended our AD-Detect® menu to include the FDA-cleared Roche Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test and launched a new AD-Detect test panel with pTau217, amyloid beta and APOE to help guide diagnosis and treatment decisions for Alzheimer's disease.

  • Advanced Project Nova from the design phase to the solutions-build phase and continue to expect to deploy Epic solutions in our first lab in the fall of 2027.

The company will hold its 2027 Investor Day on March 25, 2027, at the New York Stock Exchange. Additional information will be provided closer to the event.

| | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| | Three Months Ended September 30, | | | | | | Nine Months Ended September 30, | | | | |

| | 2026 | | 2025 | | Change | | 2026 | | 2025 | | Change |

| | (dollars in millions, except per share data) | | | | | | | | | | |

| Reported: | | | | | | | | | | | |

| Net revenues | $       3,097 | | $       2,816 | | 10.0 % | | $     9,035 | | $     8,229 | | 9.8 % |

| Diagnostic Information Services revenues | $       3,035 | | $       2,755 | | 10.2 % | | $     8,845 | | $     8,043 | | 10.0 % |

| Revenue per requisition | | | | | (4.2) % | | | | | | (2.8) % |

| Requisition volume | | | | | 14.5 % | | | | | | 12.9 % |

| Organic requisition volume | | | | | 14.4 % | | | | | | 12.8 % |

| Operating income (a) | $          479 | | $          386 | | 24.2 % | | $     1,337 | | $     1,170 | | 14.3 % |

| Operating income as a percentage of net revenues (a) | 15.5 % | | 13.7 % | | 1.8 % | | 14.8 % | | 14.2 % | | 0.6 % |

| Net income attributable to Quest Diagnostics (a) | $          312 | | $          245 | | 27.6 % | | $         884 | | $         747 | | 18.4 % |

| Diluted EPS (a) | $         2.78 | | $         2.16 | | 28.7 % | | $        7.86 | | $        6.57 | | 19.6 % |

| Cash provided by operations | $          611 | | $          563 | | 8.8 % | | $     1,486 | | $     1,421 | | 4.6 % |

| Capital expenditures | $          166 | | $          144 | | 15.0 % | | $         418 | | $         369 | | 13.2 % |

| | | | | | | | | | | | |

| Adjusted (a): | | | | | | | | | | | |

| Operating income | $          517 | | $          458 | | 13.0 % | | $     1,466 | | $     1,330 | | 10.3 % |

| Operating income as a percentage of net revenues | 16.7 % | | 16.3 % | | 0.4 % | | 16.2 % | | 16.2 % | | — % |

| Net income attributable to Quest Diagnostics | $          338 | | $          296 | | 14.2 % | | $         969 | | $         845 | | 14.7 % |

| Diluted EPS | $         3.00 | | $         2.60 | | 15.4 % | | $        8.62 | | $        7.43 | | 16.0 % |

| | |

| --- | --- |

| (a) | For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below. |

Updated Guidance for Full Year 2026

The company updates its full year 2026 guidance as follows:

| | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- |

| | Updated Guidance | | | | Prior Guidance | | |

| | Low | | High | | Low | | High |

| Net revenues | $12.065 billion | | $12.105 billion | | $11.95 billion | | $12.05 billion |

| Net revenues increase | 9.3 % | | 9.7 % | | 8.3 % | | 9.2 % |

| Reported diluted EPS | $10.21 | | $10.31 | | $9.97 | | $10.17 |

| Adjusted diluted EPS | $11.25 | | $11.35 | | $11.05 | | $11.25 |

| Cash provided by operations | Approximately $1.90 billion | | | | Approximately $1.80 billion | | |

| Capital expenditures | Approximately $550 million | | | | Approximately $550 million | | |

Note on Non-GAAP Financial Measures

As used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments and other items.

Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.

Conference Call Information

Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today.  The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at www.QuestDiagnostics.com/investor

.  We suggest participants dial in approximately 10 minutes before the call.

A replay of the call may be accessed online at www.QuestDiagnostics.com/investor

or, from approximately 10:30 a.m. Eastern Time on October 22, 2026 until midnight Eastern Time on November 5, 2026, by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers.  Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

About Quest Diagnostics

Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com

.

Forward Looking Statements

The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, the impact of the incident described in the Current Report on Form 8-K filed on October 22, 2026, uncertain and volatile economic conditions, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government policies, including related to trade, and regulations, changing relationships with customers, payers, suppliers or strategic partners, acquisitions and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.

This earnings release, including the attached financial tables, is available online in the Newsroom section at www.QuestDiagnostics.com

.

Quest Diagnostics Incorporated — Other Events Bull 0 Bear 4 Legal

On October 21, 2026, Quest Diagnostics Incorporated (the “Company”) learned of unauthorized access to its Quanum LSM system, which certain clients use to place test orders, receive and look up results. The Company promptly initiated its cybersecurity incident response procedures to contain the activity, assess and investigate the nature and scope of the incident and implement appropriate remedial measures. The Company has notified federal law enforcement authorities and engaged external cybersecurity experts to assist in the investigation and response. While the full scope of unauthorized access remains under investigation, at this time the Company believes that an unauthorized party accessed certain patient records. This incident has not materially disrupted the Company’s business operations or its ability to serve patients. The statements in this report which are not historical facts may be forward-looking statements.

10/19/2026

Half of patients with the hormonal disorder, which raises risk of heart attack, stroke and kidney disease, may be undiagnosed under current screening thresholds

SECAUCUS, N.J., Oct. 19, 2026 /PRNewswire/ -- A new study finds that current medical guidelines may inadvertently lead to under-diagnosis of primary aldosteronism (PA), a hormonal disorder associated with hypertension that can significantly raise a person's risk of heart attack, stroke and kidney disease if left untreated.

, a publication of the American Heart Association, the findings suggest that changing the diagnostic threshold for PA would double the detection rate, identifying thousands of high-risk patients who may otherwise be undiagnosed and untreated.

Researchers from Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, Mass General Brigham, Harvard Medical School and the University of Texas Southwestern Medical School conducted the study, based on deidentified results of lab tests performed by Quest on over 60,449 patients in the United States.

Primary aldosteronism occurs when the adrenal glands produce too much aldosterone, a hormone that helps regulate sodium and potassium in the blood. High blood pressure is a defining feature of the condition, though affected individuals may have other common symptoms like headaches or muscle cramps. If left untreated, several complications can occur.

In 2025

, the Endocrine Society published guidelines that recommend screening for PA for all patients with high blood pressure and included criteria for diagnosing PA. However, the new study suggests these guidelines are "overly restrictive," with laboratory cutoffs for aldosterone levels that detect only the most advanced cases of the disease. The guideline update also recommends plasma renin activity (PRA), a blood test that measures the conversion of renin in the kidneys, as the initial screening test.

When the researchers applied the 2025 criteria (PRA ≤1 ng/mL/h, aldosterone levels ≥7.5 ng/dL, ARR > 15) to the patient cohort, only 13.0% of individuals were identified as positive for PA. However, a broader, "permissive" set of criteria (PRA ≤1 ng/mL/h, aldosterone levels >5 ng/dL, without an ARR requirement) applied to the same cohort identified approximately twice as many patients, 26.2%, with PA. Additionally, clinical conditions consistent with PA such as hypertension, hypokalemia, and atrial fibrillation (based on insurance claim billing), were enriched among patients categorized as positive for PA by the more permissive laboratory cutoffs.

Among patients identified by the more permissive criteria, a PRA score of < 0.5 ng/mL/hr had 1.27 times higher odds of having hypertension compared to those with a higher (or normal) PRA (P < 0.0001). Patients with a PRA of < 0.25 ng/mL/hr had 2.62 times higher odds of having atrial fibrillation (P = 0.0032). 79.0% of the additional patients identified by permissive criteria were missed by the 2025 criteria because they had aldosterone levels between 5 and 7.5 ng/dL, below the ES cutoff, while approximately one in five had aldosterone levels that met the ES criteria but did not meet the ARR threshold.

The findings suggest the 2025 guidelines may guide physicians to identify only the more advanced forms of the disease and that primary aldosteronism should be viewed as a spectrum rather than a positive or negative diagnosis of disease. Earlier detection using more relaxed diagnostic criteria may help clinicians identify and intervene with care with potential to prevent long-term cardiovascular complications.

"Our findings demonstrate that current international clinical guidelines for diagnosing primary aldosteronism are optimized to identify advanced disease but may be less sensitive for earlier or milder forms of PA," said lead author Marco Marcelli, MD, a board-certified endocrinologist and Medical Director at Quest Diagnostics. "Some patients with PA spend years on a diagnostic journey before learning their hypertension, headaches and other symptoms are due to a highly treatable condition. More expansive screening and diagnostic criteria may help the medical community to quickly identify these individuals hiding in plain sight before irreversible heart damage and other adverse outcomes have occurred."

The study's strengths include its large patient cohort and its limitations include its retrospective design and lack of confirmatory testing.

Prompts

Quest Diagnostics Incorporated (ticker DGX), listed in United States.

ETFs Holding Quest Diagnostics Incorporated

ETF Weight in ETF Shares Market value As of
GK 3.75% 4,083 $ 1.047M Nov 17, 2026
PINK 3.63% 47,346 $ 12.137M Nov 17, 2026
JDVL 2.29% 95,276 $ 20.194M Jun 30, 2026
GDOC 1.38% 1,125 $ 270.338K Aug 31, 2026
SELV 1.14% 13,207 $ 2.799M Jun 30, 2026
MCDS 1.03% 316 $ 81.007K Nov 17, 2026
QLTY 1.01% 217,286 $ 52.214M Aug 31, 2026
VUS 0.73% 560 $ 130.486K Jul 31, 2026
VFMV 0.73% 13,685 $ 3.289M Aug 31, 2026
LSEQ 0.70% 483 $ 125.387K Nov 13, 2026
HUSV 0.61% 1,336 $ 350.313K Nov 16, 2026
ITAN 0.57% 2,735 $ 701.117K Nov 17, 2026
PAPI 0.56% 10,542 $ 2.234M Jun 30, 2026
PRAY 0.51% 1,902 $ 403.129K Jun 30, 2026
BTAL 0.45% 6,072 $ 1.287M Jun 30, 2026
SIXL 0.45% 3,639 $ 944.866K Nov 12, 2026
TMSL 0.44% 56,618 $ 12M Jun 30, 2026
FLDZ 0.41% 79 $ 16.744K Jun 30, 2026
LVDS 0.40% 1,868 $ 478.862K Nov 17, 2026
TVAL 0.32% 13,870 $ 3.637M Nov 17, 2026
DFLV 0.31% 90,609 $ 23.527M Nov 12, 2026
BAMD 0.26% 1,076 $ 258.563K Aug 31, 2026
ESUM 0.24% 1,901 $ 442.952K Jul 31, 2026
DIVN 0.24% 3,098 $ 744.449K Aug 31, 2026
ENHU 0.24% 85 $ 22.288K Nov 16, 2026
DFVX 0.17% 3,698 $ 960.186K Nov 12, 2026
DFUV 0.16% 97,281 $ 25.259M Nov 12, 2026
TACU 0.15% 103 $ 27.008K Nov 17, 2026
ESLG 0.15% 146 $ 34.019K Jul 31, 2026
IALT 0.14% 42,871 $ 11.241M Nov 16, 2026
FTLS 0.14% 13,395 $ 0.00 Nov 16, 2026
GSPY 0.11% 2,799 $ 733.926K Nov 17, 2026
AAUS 0.11% 2,138 $ 550K Nov 18, 2026
CAPE 0.11% 1,194 $ 253.068K Jun 30, 2026
NBCR 0.11% 3,745 $ 899.924K Aug 31, 2026
DXUV 0.10% 24,320 $ 6.315M Nov 12, 2026
DFAC 0.09% 320,709 $ 83.272M Nov 12, 2026
DCOR 0.09% 163,266 $ 42.392M Nov 12, 2026
APUE 0.09% 9,352 $ 2.247M Aug 31, 2026
EBI 0.08% 2,393 $ 575.038K Aug 31, 2026
XMAG 0.06% 513 $ 133.2K Nov 13, 2026
DFSU 0.06% 5,214 $ 1.354M Nov 12, 2026
DFAU 0.05% 26,073 $ 6.77M Nov 12, 2026
MODL 0.05% 2,414 $ 511.647K Jun 30, 2026
DFUS 0.04% 35,939 $ 9.332M Nov 12, 2026
VOXP 0.04% 9 $ 2,097.09 Jul 31, 2026
GDE 0.03% 648 $ 155.714K Aug 31, 2026
HCMT 0.03% 772 $ 179.884K Jul 31, 2026
NTSX 0.03% 1,924 $ 407.792K Jun 30, 2026
MSLC 0.03% 4,243 $ 1.02M Aug 31, 2026
VSLU 0.02% 588 $ 124.627K Jun 30, 2026
CSHP 0.02% 228 $ 59.784K Nov 16, 2026
AVLC 0.02% 939 $ 246.215K Nov 16, 2026
NTSD 0.02% 28 $ 5,934.60 Jun 30, 2026
DYNF 0.00% 36 $ 9,439.56 Nov 16, 2026
CORO 0.00% 70 $ 18.252K Nov 16, 2026
GVLU 0.00% 5 $ 1,311.05 Nov 17, 2026